Le Lézard
Classified in: Health, Science and technology
Subject: IMA

CELL Announces The Award of a No Objection Letter from Health Canada And The Approval of The First Ever Pivotal Stem Cell Clinical Program for Pain in The World


TORONTO, Sept. 18, 2023 /CNW/ - CELL Technologies Inc. is pleased to announce the award of a No Objection Letter (NOL) from Health Canada to launch the first ever pivotal stem cell program in pain and Osteoarthritis in the world.

"I want to congratulate all Canadians. To have the first approved pivotal stem cell program in the world being launched in Canada, is a huge victory for all of us," says CEO Dr. Riam Shammaa.

"Now patients across Canada have access to evidence-based and regulatory validated stem cells," says Dr. Shammaa.

"I want to thank the team of CELL for their great work and dedication over the years to get to this huge success," says Shammaa.

The program now allows patients with pain conditions to enroll in evidence-based and regulatory validated stem cell treatment across all Canada.

"The No Objection Letter is a significant seal of approval from Health Canada," says Dr. Gregory Murphy, Chief Medical Officer of CELL.

"It means that the regulators have reviewed and approved the efficacy of our scientific and clinical data. It also means that the regulators have reviewed and validated the safety of our processing and manufacturing, and they green light enrolling patients in the first evidence-based stem cell pivotal program in the world," says Dr. Murphy.

Based on the breakthrough data and the positive regulatory approval, CELL is now preparing to file with the FDA to get a similar approval in the US.

About CELL

CELL is a clinical stage biotech company pioneering stem cell therapy in pain medicine and inflammatory conditions, CELL's platform is based on proprietary technology in both autologous and allogeneic programs with more than 10 years of research in the field of cell therapy.

CELL is the leader in stem cell therapy in North America and aims to become the first provider of stem cells for regenerative medicine globally.

For information and for patients looking to access the stem cell program: [email protected]

SOURCE Cell Technologies Inc.


These press releases may also interest you

at 14:11
Brains Earns Great Place to Work Certification for 7th Consecutive Year
Brains is proud to be Certifiedtm by Great Place To Work® for the 7th year in a row. The prestigious award is based entirely on what current employees say about their experience working at Brains....

at 14:08
Prismatic's G2 Awards Highlight Consistent Market Leadership in Embedded iPaaS
Prismatic, the only embedded iPaaS that empowers both developers and non-developers, has been named a Momentum Leader in embedded integration platforms in G2's summer Momentum Grid® Report. The company also earned G2's Leader, Best Usability, and...

at 14:05
Demotech Research Demystifies Increased Frequency of Litigation and Social Inflation
Joseph Petrelli, President, Demotech, Inc., who authorized and initiated Demotech's ground-breaking research project in March 2022 notes with pride,  "Demotech's research, undertaken by Todd Kozikowski, identified the business model that exacerbates...

at 14:00
Marine Biotechnology Market size is set to grow by USD 4.71 billion from 2024-2028, Increase in demand for biofuel to boost the market growth, Technavio
The global marine biotechnology market size is estimated to grow by USD 4.71 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 9.83% during the forecast period. Increase in demand for biofuel is...

at 13:50
Carbon Trade eXchange (CTX) Launches ITMO Carbon Auction: Investors Can Now Enter Most Important Carbon Market on Earth
The long awaited ITMO Auction is ready to take buyer Registration via the world´s first and leading global Voluntary Carbon platform, Carbon Trade Exchange (CTX). Carbon market brokers, investors plus new players like family offices or funds can...

at 13:46
K1 Completes Strategic Exit of GoCanvas to Nemetschek Group
K1 Investment Management ("K1"), one of the largest small-cap enterprise software investment firms, yesterday completed the sale of its portfolio company GoCanvas®. GoCanvas, a leading field worker collaboration software provider, was acquired by...

More news about Science and technology...


News published on and distributed by: